Is two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan an effective regimen for advanced high-risk Hodgkin 's lymphoma?
These data indicate that combined escBEACOPP-ABVD may improve the outcome in patients with high-risk advanced HL. The potential benefit of early-interim PET activity as a guide to continuing therapy in these patients merits further study in the future.
Our results show that allogeneic apoptotic cells in combination with VD3 generate DCs with tolerogenic characteristics that could be used to induce tolerance towards alloantigens.